Andere Sprachen Plus Therapeutics, Inc.

Aktien

A3EEZB

US72941H5090

PSTV

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.06.2024			% 5 Tage	% 1. Jan.
1,47 ^USD	+0,68 %		-18,33 %	-16,00 %

07.06.	Plus Therapeutics, Inc. erhält den Rücktritt von Dr. Norman Lafrance, seinem Chief Medical Officer, mit Wirkung zum 12. Juni 2024	CI
07.06.	Plus Therapeutics erhält 3,3 Millionen Dollar Abschlagszahlung von CPRIT für radiotherapeutisches Entwicklungsprogramm	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases Phase 1 Dose Escalation Trial: Update for Initial Safety, Feasibility and Preliminary Efficacy	11.06.
Plus Therapeutics, Inc. Receives the Resignation of Dr. Norman Lafrance, Its Chief Medical Officer, Effective June 12, 2024	07.06.
Plus Therapeutics to Receive $3.3 Million Advance Payment From CPRIT For Radiotherapeutic Development Program	07.06.
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT	07.06.
Plus Therapeutics, Inc. Draws $3.3 Million on Its Existing Margin Loan Facility with Pershing Llc	04.06.
Plus Therapeutics Announces New Employment Inducement Grants	17.05.
Plus: Q1 Earnings Snapshot	15.05.
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	15.05.
Plus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024	13.05.
Plus Therapeutics : Material Agreement - Form 8-K	10.05.
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial	09.05.
Plus Therapeutics, Inc. acquired CNSide, a leptomeningeal metastases diagnostic platform.	09.05.
Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC	09.05.
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial	08.05.
Plus Therapeutics : The use of CNSide in Clinical Management of LMD	08.05.
Plus Therapeutics Announces Private Placement Financing of up to $18 Million	06.05.
Plus Therapeutics, Inc. announced that it expects to receive $6.548504 million in funding from Aigh Capital Management, LLC	05.05.
Plus Therapeutics : Nuclear Medicine and Neurooncology (NMN) Symposium 2024	29.04.
Plus Therapeutics Gets $3 Million Funding Recommendation From Department of Defense	22.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Plus Therapeutics, Inc.

Aktien

A3EEZB

US72941H5090

PSTV

Andere Sprachen

Filter